Formalizing a longstanding collaboration to unite patient advocacy and market expertise to drive advancements in kidney patient care. EXTON, PA.,
There are signs Bimzelx is affecting the psoriatic arthritis market. UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global
Rheumatologists’ perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch
Analysis of over 1,000 chronic kidney disease patient charts shows GLP-1 receptor agonist use nearly doubling from 2023 to 2024.
Despite greater physician pre-approval familiarity with Omvoh compared to J&J Innovative Medicine’s Tremfya, gastroenterologists favor Tremfya over Omvoh for Crohn’s
Currently, many lupus nephritis treating rheumatologists and nephrologists delay initiating triple therapy, with a significant portion deferring a triple therapy
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to
Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $220 from $212 and keeps an
Spherix Global Insights Announces New Study on Impact of Inflation Reduction Act (IRA) on Specialty Practices and Key Insights for
Spherix Global Insights’ analysis of over 200 PNH patient records reveal current treatment patterns and opportunities for emerging therapies, including
Spherix Global Insights notes that differentiation among the IL-23 therapies “will be essential” as Tremfya and Omvoh look to battle
Findings from Spherix Global Insights show that practitioners consider nearly half of their C3G patients to be potential candidates for
